+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Inflammatory Bowel Syndrome Treatment Market - Forecasts from 2023 to 2028

  • PDF Icon


  • 140 Pages
  • April 2023
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5794059
The inflammatory bowel syndrome (IBS) treatment market was valued at US$22.529 billion in 2021 and will witness robust growth over the projected period. Inflammatory bowel syndrome is a chronic digestive disorder that affects the large intestine (colon) and causes symptoms such as abdominal pain, bloating, diarrhea, and constipation. It is a complicated illness with no known cure, and its precise cause is unclear. As a result, the IBS industry offers various medications and therapies designed to control and lessen the condition's symptoms. The two primary categories of these treatments are pharmacological and non-pharmacological. Laxatives, anti-diarrheal medicines, antispasmodics, and antidepressants are a few examples of the pharmaceuticals used pharmacologically to treat IBS. By focusing on particular IBS symptoms, such as decreased bowel contractions, increased frequency of stools, or mood enhancement, these drugs seek to alleviate the symptoms of the condition.

Dietary changes, such as increasing fiber intake or avoiding particular trigger foods, and lifestyle improvements, such as stress management and exercise, are examples of non-pharmacological therapy for IBS. Additional treatment options like supplementary and alternative therapies include acupuncture or hypnosis, which some patients may find helpful. The development of novel and innovative treatments, the rising prevalence of the illness, rising awareness of IBS among patients and healthcare professionals, and other factors are projected to fuel the growth of the IBS treatment market in the upcoming years. However, the market also has to contend with issues like the high cost of some pharmaceuticals and the ineffectiveness of some patients' present treatments.

The inflammatory bowel syndrome treatment market is driven by the rising cases and awareness of IBS and by the introduction and improvements in diagnostic procedures.

  • The rising prevalence of inflammatory bowel syndrome is one of the main factors driving the IBS treatment market, which is caused by various variables such as changes in food, lifestyle, and gut microbiota. Changes in gut flora have also been linked to the development of IBS and these lifestyle factors. IBS affects between 25 and 45 million Americans, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
  • Increasing awareness of IBS among patients and healthcare professionals is another important factor driving the IBS treatment market. Advanced knowledge of the issue may result in earlier diagnosis and treatment, improving patient outcomes.
  • Improvements in diagnostic technology are also fuelling the growth of the IBS treatment market, which increases the precision and efficiency of IBS diagnosis. Recent years have seen the development of several diagnostic tests that can help confirm an IBS diagnosis and rule out other illnesses that might present with comparable symptoms. For example, the American College of Gastroenterology suggests using certain diagnostic procedures to diagnose IBS, including colonoscopies and fecal calprotectin assays. The U.S. Food and Drug Administration (FDA) also approved

    tenapanor in 2020 for treating IBS with constipation in adults.

The key challenges to the market growth are high-cost treatments and limited knowledge and efficiency of treatment solutions.

Since many available IBS treatments are only partially effective, many patients only get insufficient symptom relief. Antispasmodics and antidepressants, for example, might have considerable adverse effects that restrict their acceptability when used as IBS therapy. In addition, some of the more recent IBS medications, such as biologics, can be pricey, which limits some patients' access to them. These reasons significantly hamper the development of the IBS treatment market.

Market Developments:

In May 2022, the Indian Council of Medical Research (ICMR) released the IBD NutriCare App for patients suffering from inflammatory bowel disease (IBD). The ICMR, a group of gastroenterologists, dieticians, and app developers from AIIMS, collaborated to create the IBD NutriCare App targeted at the IBD population in India. It offers real-time data that informs the nutritionist or dietician about compliance problems, inaccurate entries, and inaccurate information, assisting in launching early and prompt nutritional interventions and creating individualized diet programs. It is mainly concentrated on the ease of large-scale data collecting and personalized tele-nutrition counseling that can improve the general clinical practice of dietary control and nutrition in IBD in a resource-constrained country like India.

Asia Pacific and North America accounted for a major share of the inflammatory bowel syndrome treatment market.

The inflammatory bowel syndrome treatment market is segmented geographically into North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America is anticipated to control significant shares of the global IBS market due to the region's high incidence of the ailment and numerous big pharmaceutical companies. According to the Canadian Society of Intestinal Research, IBS is estimated to affect between 5% and 20% of Canadians. Additionally, the region has a strong healthcare infrastructure and high public and professional knowledge of IBS. As a result, developing novel and creative remedies for the illness has become a priority.

The Asia Pacific IBS treatment market is predicted to rise significantly due to the region's huge and expanding population and the ailment's rising prevalence. IBS is also becoming more widely known in the area, which has boosted the demand for diagnostic procedures and treatment alternatives. A number of significant pharmaceutical companies have also established operations in the area, which has increased investment in R&D.

Market Segmentation:

By Type

  • Irritable Bowel Syndrome with Diarrhea (IBS-D)
  • Irritable Bowel Syndrome with Constipation (IBS-C)
  • Post-infectious IBS (IBS-PI)
  • Others

By Treatment Type

  • Medications
  • Psychological Therapy
  • Dietary Supplements
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Vietnam
  • Indonesia
  • Others

Table of Contents

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
2.1. Research Data
2.2. Research Design
2.3. Validation
3.1. Research Highlights
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5.1. Introduction
5.2. Inflammatory Bowel Syndrome with Diarrhea (IBS-D)
5.3. Inflammatory Bowel Syndrome with Constipation (IBS-C)
5.4. Post-infectious IBS (IBS-PI)
5.5. Others
6.1. Introduction
6.2. Medications
6.3. Psychological Therapy
6.4. Dietary Supplements
6.5. Others
7.1. Introduction
7.2. North America
7.2.1. USA
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. United Kingdom
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Others
7.5. Middle East And Africa
7.5.1. Saudi Arabia
7.5.2. Israel
7.5.3. UAE
7.5.4. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. Japan
7.6.3. India
7.6.4. South Korea
7.6.5. Australia
7.6.6. Vietnam
7.6.7. Indonesia
7.6.8. Others
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9.1. AbbVie Inc.
9.2. Ironwood Pharmaceuticals
9.3. Bayer AG
9.4. Probi AB
9.5. Salix Pharmaceuticals
9.6. Cosmo Pharmaceuticals
*Not an exhaustive list

Companies Mentioned

  • AbbVie Inc.
  • Ironwood Pharmaceuticals
  • Bayer AG
  • Probi AB
  • Salix Pharmaceuticals
  • Cosmo Pharmaceuticals